Taselisib is under clinical development by Genentech USA and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Taselisib’s likelihood of approval (LoA) and phase transition for Diffuse Large B-Cell Lymphoma took place on 06 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 06 Sep 2021 increased Taselisib’s LoA and PTSR for Non-Hodgkin Lymphoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Taselisib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Taselisib overview

Taselisib (GDC-0032, RG-7604) is under development for the treatment of non-Hodgkin lymphoma and diffuse large B-cell lymphoma. It is administered orally as a tablet. Taselisib acts by targeting PI3K-alpha. It was also under development for the treatment of squamous non-small cell lung cancer as second-line therapy. It was also under development for advanced or metastatic solid tumors including estrogen receptor-positive and HER2-negative (ER+/HER2-) metastatic breast cancer as second-line therapy, first line and neoadjuvant therapy.

Genentech USA overview

Genentech USA (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. Its pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International, Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.

Quick View Taselisib LOA Data

Report Segments
  • Innovator
Drug Name
  • Taselisib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.